←
BioInvent International203 posts
BioInvent International avatar

BioInvent International

@BioInvent

BioInvent is a clinical-stage biotech company (Nasdaq Stockholm: BINV) that translates cancer antibody biology into innovative immuno-oncology therapies.

◷ Joined May 2021▧ 96 Photos and videos
Pareto Securities avatar
⟳ BioInvent International retweeted
Pareto Securities@ParetoSec·19 Sep 2024

Many overlook the importance of toxicity. Martin Welschof, CEO of BioInvent says: Toxicity is as crucial as efficacy. You can’t use what kills you.' A reminder that safety is at least as important as effectiveness in treatments. @BioInvent $BINV is one of the presenting companies at our 15th annual Healthcare Conference today. For all our BioInvent research, access our research and online trading platform (for clients): paretosec.com/updates/events…

Post attachment
BioInvent International avatar
BioInvent International@BioInvent·22 Jul 2024

BioInvent to Present Pipeline Progress at ESMO in September 2024. Two posters to be presented on early clinical projects from BioInvent’s robust pipeline totaling six clinical programs. - Progress Phase 1 update for BI-1910 - Initial Phase 1 clinical data for BT-001

Post attachment
BioInvent International avatar
BioInvent International@BioInvent·19 Jun 2024

Did you miss our KOL event yesterday? No worries, watch it here, anytime: lifescievents.com/event/bioi… The event features Alexander Eggermont, MD, PhD (University Medical Center Utrecht), on the topic "Where are we going next with immuno-oncology?" and CEO, CMO and CSO.